B Group Inc. Acquires New Shares in Aura Biosciences, Inc. (NASDAQ:AURA)

B Group Inc. acquired a new position in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 472,576 shares of the company's stock, valued at approximately $3,885,000. Aura Biosciences comprises 2.4% of B Group Inc.'s portfolio, making the stock its 8th largest holding. B Group Inc. owned 0.95% of Aura Biosciences at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Levin Capital Strategies L.P. increased its stake in shares of Aura Biosciences by 169.1% during the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock worth $10,255,000 after purchasing an additional 783,984 shares during the period. Franklin Resources Inc. increased its position in Aura Biosciences by 14.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock worth $15,571,000 after buying an additional 215,597 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company's stock worth $15,764,000 after buying an additional 112,296 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Aura Biosciences by 25.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 365,824 shares of the company's stock valued at $3,007,000 after acquiring an additional 73,062 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Aura Biosciences by 489.4% in the fourth quarter. Renaissance Technologies LLC now owns 83,700 shares of the company's stock valued at $688,000 after acquiring an additional 69,500 shares in the last quarter. Institutional investors own 96.75% of the company's stock.

Insiders Place Their Bets

In related news, insider Conor Kilroy sold 7,162 shares of the firm's stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total value of $39,319.38. Following the transaction, the insider now owns 179,313 shares of the company's stock, valued at approximately $984,428.37. This trade represents a 3.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 14,148 shares of company stock worth $91,434. 5.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

AURA has been the subject of several analyst reports. Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright set a $25.00 price target on Aura Biosciences in a research note on Tuesday, March 25th. Citigroup reissued an "outperform" rating on shares of Aura Biosciences in a research report on Wednesday, March 26th. Finally, JMP Securities set a $19.00 price objective on Aura Biosciences in a report on Wednesday, March 26th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Aura Biosciences presently has an average rating of "Buy" and an average target price of $22.75.

Aura Biosciences Price Performance

Shares of AURA stock traded down $0.14 on Friday, hitting $5.38. 244,554 shares of the company's stock were exchanged, compared to its average volume of 201,935. The company has a 50 day moving average of $6.48 and a 200 day moving average of $8.06. The stock has a market cap of $270.21 million, a P/E ratio of -3.11 and a beta of 0.43. Aura Biosciences, Inc. has a 12 month low of $4.84 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09). Sell-side analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.